Jaguar Health Reports Unregistered Equity Sales
Ticker: JAGX · Form: 8-K · Filed: 2024-06-10T00:00:00.000Z
Sentiment: neutral
Topics: unregistered-securities, equity-sale, disclosure
TL;DR
Jaguar Health sold unregistered equity, watch for dilution.
AI Summary
Jaguar Health, Inc. filed an 8-K on June 10, 2024, reporting unregistered sales of equity securities. The filing details transactions that occurred on June 7, 2024, related to the company's operations in the pharmaceutical preparations sector.
Why It Matters
This filing indicates potential dilution for existing shareholders due to the issuance of new equity without a prior public offering.
Risk Assessment
Risk Level: medium — Unregistered sales can signal financial distress or a need for quick capital, potentially impacting stock value.
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- June 7, 2024 (date) — Date of earliest event reported
- June 10, 2024 (date) — Date of report
- 200 Pine Street , Suite 400 San Francisco , California 94104 (address) — Principal executive offices
FAQ
What type of securities were sold in the unregistered offering?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the exact type of equity in the provided text.
Were these sales part of a financing round or a specific agreement?
The filing indicates 'Unregistered Sales of Equity Securities' as an item of disclosure, but the specific context or purpose of these sales is not detailed in the provided excerpt.
What is the total number of shares sold and the price per share?
The provided text does not contain specific details on the number of shares sold or the price per share in the unregistered sale.
Who were the purchasers of these unregistered securities?
The filing mentions 'Unregistered Sales of Equity Securities' but does not identify the purchasers in the excerpt.
Does this filing relate to any ongoing legal or regulatory matters for Jaguar Health?
The filing is specifically for 'Unregistered Sales of Equity Securities' and 'Financial Statements and Exhibits', and does not explicitly mention any ongoing legal or regulatory matters in the provided text.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-06-10 12:19:15
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Mar
- $1,500,000 — stock to such holder in exchange for a $1,500,000 reduction in the outstanding balance of
Filing Documents
- tm2416853d1_8k.htm (8-K) — 26KB
- 0001104659-24-069958.txt ( ) — 196KB
- jagx-20240607.xsd (EX-101.SCH) — 3KB
- jagx-20240607_lab.xml (EX-101.LAB) — 33KB
- jagx-20240607_pre.xml (EX-101.PRE) — 22KB
- tm2416853d1_8k_htm.xml (XML) — 4KB
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. On June 7, 2024, Jaguar Health, Inc. (the "Company") entered into a privately negotiated exchange agreement (the "Exchange Agreement") with a holder of royalty interest in the Company. Pursuant to the Exchange Agreement, the Company issued 393,700 shares of common stock to such holder in exchange for a $1,500,000 reduction in the outstanding balance of the royalty interest held by such holder. The shares of common stock that were issued in the exchange transaction described above were issued in reliance on the exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933, as amended. The form of Exchange Agreement was filed as Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019 , filed on August 14, 2019, which is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Form of Exchange Agreement (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019, filed on August 14, 2019). 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: President and Chief Executive Officer Date: June 10, 2024